Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous HPV16 peptide-pulsed dendritic cell therapy
- Development stage
- Unknown
- Lead developer
- People's Hospital of Xinjiang Uygur Autonomous Region
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Parenteral
01
Overview
Autologous HPV16 peptide-pulsed dendritic cell therapy is an experimental, patient-specific cell-based immunotherapy developed by the People's Hospital of Xinjiang Uygur Autonomous Region. It is designed for the treatment of advanced, HPV16-positive cervical cancer in patients who have exhausted standard treatment options. The therapy involves harvesting a patient's own dendritic cells (DCs), pulsing them ex vivo with peptides derived from the HPV16 E6 and E7 oncoproteins, and reinfusing them to prime and activate the patient's immune system. This approach aims to induce a robust HPV16-specific cytotoxic T lymphocyte (CTL) response targeted against tumor cells expressing these viral antigens. It is currently being evaluated in early-phase clinical studies to assess safety and preliminary efficacy in patients with stage IIIB or higher cervical cancer.
- Other names
- autologous HPV16 peptide-pulsed dendritic cell therapyDC-CTL cell therapyautologous dendritic cell (DC)–based HPV16-specific cytotoxic T lymphocyte (CTL) immunotherapy
02
Targets
Human papillomavirus type 16 E7-derived peptide epitopeHPV16 E6 oncoprotein
Beyond the preview
Go deeper on autologous HPV16 peptide-pulsed dendritic cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous HPV16 peptide-pulsed dendritic cell therapy.